Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Allison Owings

Nurse Practitioner, Family Dakota Dunes, SD Nurse Practitioner

NPI 1417435462 CMS profile 10615011

575 N Sioux Point Rd, Dakota Dunes, SD 57049

Open in the dashboard

General payments

$4,360

213 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Allison Owings of Dakota Dunes, SD is reported in the CMS Open Payments database as having received $4,360 across 213 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,295 83
2024 General $1,593 38
2023 General $930 58
2022 General $291 12
2021 General $251 22

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Allison Owings
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Allison Owings were reported at $1,295. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Allison Owings Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $251 $124 $35–$379 $132
2022 $291 $141 $44–$430 $149
2023 $930 $154 $49–$476 $160
2024 $1,593 $165 $51–$504 $164
2025 $1,295 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Abbott Laboratories $1,275 20 payments
  2. AbbVie, Inc. $1,051 93 payments
  3. Teva Pharmaceuticals USA, Inc. $548 22 payments
  4. Lundbeck LLC $233 10 payments
  5. Pfizer Inc. $208 25 payments
  6. Argenx US, Inc. $153 6 payments
  7. Inspire Medical Systems, Inc. $143 3 payments
  8. Biohaven Pharmaceutical Holding Company Ltd. $137 4 payments
  9. Lilly USA, LLC $94 6 payments
  10. ACADIA Pharmaceuticals Inc $83 4 payments
  11. Other $436 20 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $3,270 205 payments
  2. Travel and Lodging $902 6 payments
  3. Education $188 2 payments
Products named General payments · program years 2021–2025
  1. INFINITY Neuromodulation $1,103 14 payments
  2. UBRELVY $683 77 payments
  3. QULIPTA $497 36 payments
  4. NURTEC ODT Pain $208 25 payments
  5. ZAVZPRET $208 25 payments
  6. Austedo XR $196 13 payments
  7. BOTOX $189 11 payments
  8. INFINITY Structural Heart $172 6 payments
  9. VYEPTI $164 7 payments
  10. NURTEC ODT Primary Care $151 5 payments
  11. Other $905 40 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 75 drugs

Part D claims

4,615

Median for Nurse Practitioner: 389

Drug cost

$1,321,491

Median for Nurse Practitioner: $21,885

Branded share of claims

34.7%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Austedo Deutetrabenazine Brand 16 $188,636
Avonex Pen (4 Pack) Interferon Beta-1a Brand 23 $187,065
Aubagio Teriflunomide Brand 14 $129,532
Avonex (4 Pack) Interferon Beta-1a Brand 12 $101,055
Aimovig Autoinjector Erenumab-Aooe Brand 120 $96,398
Nurtec Odt Rimegepant Sulfate Brand 69 $89,854
Copaxone Glatiramer Acetate Brand 12 $83,998
Glatopa Glatiramer Acetate Brand 27 $47,821
Lamictal Xr Lamotrigine Brand 25 $41,790
Emgality Pen Galcanezumab-Gnlm Brand 44 $31,638

The 10 drugs with the highest cost, of 75 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 43 billing codes

Paid by Medicare

$62,014

Of which drugs: $8,958

Medicare patients

480

Average age 72

Services billed

3,120

262 women, 218 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Arthritis 44%
Depression 33%
Diabetes 29%
Chronic kidney disease 29%
Ischemic heart disease 23%
COPD 19%
Atrial fibrillation 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
UBRELVY
  • AbbVie, Inc. $88
$88 29 —
QULIPTA
  • AbbVie, Inc. $81
$81 — —
VALTOCO
  • Neurelis, Inc. $35
$35 11 —
VYEPTI
  • Lundbeck LLC $24
$24 — —
EMGALITY
  • Lilly USA, LLC $24
$24 44 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

213 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in South Dakota

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record